Association between autoimmune diseases and COVID-19 as assessed in both a test-negative case–control and population case–control design
Tóm tắt
COVID-19 epidemic has paralleled with the so called infodemic, where countless pieces of information have been disseminated on putative risk factors for COVID-19. Among those, emerged the notion that people suffering from autoimmune diseases (AIDs) have a higher risk of SARS-CoV-2 infection. The cohort included all COVID-19 cases residents in the Agency for Health Protection (AHP) of Milan that, from the beginning of the outbreak, developed a web-based platform that traced positive and negative cases as well as related contacts. AIDs subjects were defined ad having one the following autoimmune disease: rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjogren disease, ankylosing spondylitis, myasthenia gravis, Hashimoto’s disease, acquired autoimmune hemolytic anemia, and psoriatic arthritis. To investigate whether AID subjects are at increased risk of SARS-CoV-2 infection, and whether they have worse prognosis than AIDs-free subjects once infected, we performed a combined analysis of a test-negative design case–control study, a case–control with test-positive as cases, and one with test-negative as cases (CC-NEG). During the outbreak, the Milan AHP endured, up to April 27th 2020, 20,364 test-positive and 34,697 test-negative subjects. We found no association between AIDs and being positive to COVID-19, but a statistically significant association between AIDs and being negative to COVID-19 in the CC-NEG. If, as likely, test-negative subjects underwent testing because of respiratory infection symptoms, these results imply that autoimmune diseases may be a risk factor for respiratory infections in general (including COVID-19), but they are not a specific risk factor for COVID-19. Furthermore, when infected by SARS-CoV-2, AIDs subjects did not have a worse prognosis compared to non-AIDs subjects. Results highlighted a potential unbalance in the testing campaign, which may be correlated to the characteristics of the tested person, leading specific frail population to be particularly tested. Lack of availability of sound scientific knowledge inevitably lead unreliable news to spread over the population, preventing people to disentangle them form reliable information. Even if additional studies are needed to replicate and strengthen our results, these findings represent initial evidence to derive recommendations based on actual data for subjects with autoimmune diseases.
Tài liệu tham khảo
Orso D, Federici N, Copetti R, et al. Infodemic and the spread of fake news in the COVID-19-era. Eur J Emerg Med. 2020. https://doi.org/10.1097/MEJ.0000000000000713.
Mitchell DM, Spitz PW, Young DY, et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum. 1986;29:706–14. https://doi.org/10.1002/art.1780290602.
Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481–94. https://doi.org/10.1002/art.1780370408.
Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol. 1998;25:1072–7.
Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35:387–93.
Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–93. https://doi.org/10.1002/art.10524.
Tektonidou MG, Wang Z, Dasgupta A, Ward MM. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based Study, 1996–2011. Arthritis Care Res. 2015;67:1078–85. https://doi.org/10.1002/acr.22575.
Bosch X, Guilabert A, Pallarés L, et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus. 2006;15:584–9. https://doi.org/10.1177/0961203306071919.
Pene F, Merlat A, Vabret A, et al. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis. 2003;37:929–32. https://doi.org/10.1086/377612.
Horisberger A, Moi L, Ribi C, Comte D. Autoimmune diseases in the context of pandemic COVID-19. Rev Med Suisse. 2020;16:827–30.
Favalli EG, Ingegnoli F, De Lucia O, et al. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev. 2020;19:102523. https://doi.org/10.1016/j.autrev.2020.102523.
Askanase AD, Khalili L, Buyon JP. Thoughts on COVID-19 and autoimmune diseases. Lupus Sci Med. 2020;7:e000396. https://doi.org/10.1136/lupus-2020-000396.
Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res. 2011;31:887–92. https://doi.org/10.1089/jir.2011.0071.
D’Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’. Ann Rheum Dis. 2020;79(9):1156–62.
Liu M, Gao Y, Zhang Y, et al. The association between severe or death COVID-19 and autoimmune disease: a systematic review and meta-analysis. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.05.065.
Emmi G, Bettiol A, Mattioli I, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev. 2020;19:102575. https://doi.org/10.1016/j.autrev.2020.102575.
International MG/COVID-19 Working Group, Jacob S, Muppidi S, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;412:116803. https://doi.org/10.1016/j.jns.2020.116803.
Price E, MacPhie E, Kay L, et al. Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic. Clin Med. 2020. https://doi.org/10.7861/clinmed.2020-0160.
Matucci-Cerinic M, Bruni C, Allanore Y, et al. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann Rheum Dis. 2020;79:724–6. https://doi.org/10.1136/annrheumdis-2020-217407.
Pope JE. What does the COVID-19 pandemic mean for rheumatology patients? Curr Treatm Opt Rheumatol. 2020. https://doi.org/10.1007/s40674-020-00145-y.
Price E, MacPhie E, Kay L, et al. Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic. Clin Med. 2020. https://doi.org/10.7861/clinmed.2020-0160.
Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79:667–8. https://doi.org/10.1136/annrheumdis-2020-217424.
Nicastri E, Petrosillo N, Bartoli TA, et al. National Institute for the infectious diseases “L. Spallanzani” IRCCS recommendations for COVID-19 clinical management. Infect Dis Rep. 2020. https://doi.org/10.4081/idr.2020.8543.
Attivazione della presa in carico dei pazienti cronici e fragili: DGR n. X/6164 del 30.01.17 “Governo della domanda.” https://www.regione.lombardia.it/wps/portal/istituzionale/HP/DettaglioRedazionale/servizi-e-informazioni/Enti-e-Operatori/sistema-welfare/attuazione-della-riforma-sociosanitaria-lombarda/avvio-presa-carico-pazienti-cronici-fragili/dgr2017-6164-avvio-presa-carico-pazienti-cronici-fragili. Accessed 14 Jul 2020.
Avvio del percorso di presa in carico dei pazienti cronici e fragili: DGR n. X/7655 del 28.12.17. https://www.regione.lombardia.it/wps/portal/istituzionale/HP/DettaglioRedazionale/servizi-e-informazioni/Enti-e-Operatori/sistema-welfare/attuazione-della-riforma-sociosanitaria-lombarda/dgr2017-7655-avvio-presa-carico-cronici/dgr2017-7655-avvio-presa-carico-cronici. Accessed 14 Jul 2020.
Vandenbroucke JP, Brickley EB, Vandenbroucke-Grauls CMJE, Pearce N (2020) The test-negative design with additional population controls: a practical approach to rapidly obtain information on the causes of the SARS-CoV-2 epidemic. arXiv:200406033 [q-bio, stat].
Kelly S Fitting a Cumulative Logistic Regression Model. 5.
22954-The PROC LOGISTIC proportional odds test and fitting a partial proportional odds model. https://support.sas.com/kb/22/954.html. Accessed 17 Jun 2020.
Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020;80:639–45. https://doi.org/10.1016/j.jinf.2020.03.019.
Du R-H, Liu L-M, Yin W, et al. Hospitalization and critical care of 109 decedents with COVID-19 Pneumonia in Wuhan. China: Ann Am Thorac Soc; 2020. https://doi.org/10.1513/AnnalsATS.202003-225OC.
Wei Y-y, Wang R-R, Zhang D-W, et al. Risk factors for severe COVID-19: evidence from 167 hospitalized patients in Anhui, China. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.04.010.
Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020. https://doi.org/10.1136/bmj.m1091.